CTRI/2019/08/020563尚未招募4 期
A randomized, double â?? blind, comparative trial of combined topical adapalene (0.1%) andbenzoyl peroxide (2.5%) versus topical benzoyl peroxide (2.5%) monotherapy in grade I and IIAcne vulgaris - ABPAV
KPC Medical College and Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Untreated male and non-pregnant female above 15 years.
- •2. Acute, symptomatic Acne vulgaris patients of moderate variety.
- •3. Those with comedones and papules
排除标准
- •1. Pregnant or nursing females.
- •2. Patients with Diabetes Mellitus, Malignancy, renal or hepatic
- •dysfunction
- •3. History of hypersensitivity to any of the study drugs.
- •4. Patients not willing to comply with protocol requirements.
- •5. Those who received steroids in last 3 months.
研究者
相似试验
进行中（未招募）
1 期
Occurrence of hypophosphataemia in patients with iron deficiency anemia caused by inflammatory bowel disease after treatment with iron isomaltoside or iron carboxymaltoseEUCTR2017-002452-87-DKPharmacosmos A/S120
进行中（未招募）
1 期
A study comparing the incidence of low phosphate levels in the blood (hypophosphatemia) after treatment with iron isomaltoside (Monofer®) and ferric carboxymaltose (Ferinject®) in patients with iron deficiency anaemia (low red blood cell count due to low iron levels in the blood) caused by swelling in the gut (known as inflammatory bowel disease).Iron deficiency anaemia due to inflammatory bowel diseaseMedDRA version: 20.0Level: LLTClassification code 10002062Term: Anaemia iron deficiencySystem Organ Class: 100000004851EUCTR2017-002452-87-GBPharmacosmos A/S120
进行中（未招募）
1 期
Occurrence of hypophosphataemia in patients with iron deficiency anemia caused by inflammatory bowel disease after treatment with ironisomaltoside or iron carboxymaltoseEUCTR2017-002452-87-DEPharmacosmos A/S120
进行中（未招募）
1 期
Occurrence of hypophosphataemia in patients with iron deficiency anemia caused by inflammatory bowel disease after treatment with iron isomaltoside or iron carboxymaltoseIron deficiency anemia in subject with inflammatory bowel diseaseMedDRA version: 20.0Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0Level: LLTClassification code 10079322Term: Anaemia of chronic inflammationSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2017-002452-87-SEPharmacosmos A/S120
进行中（未招募）
1 期
Occurrence of hypophosphataemia in patients with iron deficiency anemia caused by inflammatory bowel disease after treatment with ironisomaltoside or iron carboxymaltoseEUCTR2017-002452-87-ATPharmacosmos A/S120